In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settingsUtility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapyResults from the JAVELIN trial on avelumab maintenance after chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapyPresenters:Thomas Powles, MBBS, MRCP, MDDeputy Centre LeadCentre for Experimental Cancer MedicineBarts Cancer InstituteQueen Mary University of LondonProfessor of Urology CancerDirector of Barts Cancer CentreDepartment of CancerSt Bartholomew's Hospital (Barts Health NHS Trust)London, United KingdomMichiel van der Heijden, MD, PhDMedical Oncologist and Research Group LeaderDepartment of Medical Oncology and Molecular CarcinogenesisStichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek ZiekenhuisMedical Oncologist Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer InstituteAmsterdam, the NetherlandsContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:https://bit.ly/3kJC5SL

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related